Not for distribution to United States newswire services or for dissemination in the United StatesQUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical phar
DULUTH, Ga.--(BUSINESS WIRE)--#ComClassic--AGCO Corporation (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology, will be among the headliners at the 2024 Commodity Classic, with a
Fourth quarter results reflect strong fertilizer market fundamentals in North America. Expect increased fertilizer sales volumes and growth in Retail earnings in 2024. All amounts are in US dollars except as otherwise notedSASKATOON, Saskatchewan--(BUSIN
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, t
$225 million to be invested into Cincinnati facility to increase PFS and Cartridge fill/finish capabilities Expanding Research Triangle Park (RTP) fill/finish operations, building on company’s existing fill/finish capabilities in Toronto and Cincinnati
OTTAWA, Ontario--(BUSINESS WIRE)--#ait--The Canadian Alliance for Skills and Training in Life Sciences (CASTL) and BioTalent Canada have partnered to deliver innovative training as part of CASTL’s new national program Elevate. The CASTL Elevate program,
QUÉBEC, Québec--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical pharmaceutical and c
BEIJING--(BUSINESS WIRE)--#Antibody--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc. The agreement provides Gilead access to Biocytogen
With a Focus on Potential Pivotal Studies in 2025, Treadwell has Strengthened its Leadership Team by Appointing Brenda Marczi, PharmD, MBA as SVP and Head of Regulatory AffairsTORONTO & SAN FRANCISCO--(BUSINESS WIRE)--Treadwell Therapeutics, a privately
Total revenue of $38 million, compared to $485 million in FY 2022 Total cumulative partner-initiated program starts with downstreams of 87, with 12 new starts in the year Net loss of $0.51 per share on a basic and diluted basis, compared to earnings o
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.